Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Chronic inflammation represents a central component in the pathogenesis of Alzheimer's disease (AD). Recent work suggests that breaking immune tolerance by Programmed cell Death‐1 (PD1) checkpoint inhibition produces an IFN‐γ‐dependent systemic immune response, with infiltration of the brain by peripheral myeloid cells and neuropathological as well as functional improvements even in mice with advanced amyloid pathology (Baruch et al., (): Nature Medicine, 22:135–137). Immune checkpoint inhibition was therefore suggested as potential treatment for neurodegenerative disorders when activation of the immune system is appropriate. Because a xenogeneic rat antibody (mAb) was used in the study, whether the effect was specific to PD1 target engagement was uncertain. In the present study we examined whether PD1 immunotherapy can lower amyloid‐β pathology in a range of different amyloid transgenic models performed at three pharmaceutical companies with the exact same anti‐PD1 isotype and two mouse chimeric variants. Although PD1 immunotherapy stimulated systemic activation of the peripheral immune system, monocyte‐derived macrophage infiltration into the brain was not detected, and progression of brain amyloid pathology was not altered. Similar negative results of the effect of PD1 immunotherapy on amyloid brain pathology were obtained in two additional models in two separate institutions. These results show that inhibition of PD1 checkpoint signaling by itself is not sufficient to reduce amyloid pathology and that additional factors might have contributed to previously published results (Baruch et al., (): Nature Medicine, 22:135–137). Until such factors are elucidated, animal model data do not support further evaluation of PD1 checkpoint inhibition as a therapeutic modality for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 4×
“We sought to confirm the efficacy of anti-PD1 treatment in a range of different amyloid-developing transgenic models used extensively for pharmacological testing in our respective groups (Asberom et al., 2007; Blanchard et al., 2003; Deleye et al., 2017; Games et al., 1995; Hansen et al., 2016; Janus et al., 2000).”
BackgroundInfluentialJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 2×
“The discrepancy in results potentially could also come from the different genetic backgrounds of the transgenic models used by Baruch (5xFAD: BL6SJL and APP/PS1: BL6C3) versus the ones used in our current report, however we used three different genetic backgrounds (Table 1), making this less likely.”
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 2×
“21-month old APP/PS1 animals (Radde et al., 2006) led to the same conclusion (data not shown).”
BackgroundResultReduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865 · cited 1×
“…immunity to AD pathogenesis is poorly understood; and whether and how these systems should be modulated to improve AD pathology is unclear (Alves et al., 2017; Browne et al., 2013; Dansokho et al., 2016; Marsh et al., 2016; Spani et al., 2015; Yang, Yang, Xie, Wei, & Bi, 2013; Zenaro et al., 2015).”
BackgroundThe role of peripheral immune cells in the CNS in steady state and disease
Prinz, M., & Priller, J. (2017) · Nature Neuroscience · doi:10.1038/nn.4475 · Cited by 657 · cited 2×
“The peripheral immune system is clearly implicated in AD pathogenesis (Heneka et al., 2015; Prinz & Priller, 2017).”
BackgroundMechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527 · cited 2×
“Inflammation is a central component in the pathogenesis of AD with both the innate and adaptive immune systems implicated, although their respective role remains unclear (Heneka et al., 2015; Ries & Sastre, 2016).”
BackgroundBaruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491 · cited 2×
“IFN-c in the choroid plexus Previous work demonstrated that PD-1 blockade leads to an increase of IFN-g-transcription in the CP allowing peripheral myeloid cell trafficking into the brain (Baruch et al., 2016; Baruch et al., 2015).”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 1×
“All mice used in this study were bred and housed in Taconic using a breeding strategy as previously described (Demattos et al., 2012) and all experiments were performed in accordance with the Institutional Animal Care and Use Guidelines for Eli Lilly.”
MethodSelf-citationBaruch, K., Deczkowska, A., Rosenzweig, N., Tsitsou-Kampeli, A., Sharif, A. M., Matcovitch-Natan, O., Kertser, A., David, E., Amit, I., & Schwartz, M. (2016) · Nature Medicine · doi:10.1038/nm.4022 · Cited by 425 · cited 17×
“For antiPD1 treatments, we used either the exact same RMP1–14 rat IgG2a mAb as previously published (Baruch et al., 2016) a chimeric version with a mouse IgG1 (mu anti-mPD1) or mouse IgG2 Fc domains to reduce immunogenicity upon repeated administration) to cover a broad spectrum of experimental…”
BackgroundMethodResultInfluentialBaik, S. H., Kang, S., Son, S. M., & Mook-Jung, I. (2016) · Glia · doi:10.1002/glia.23074 · Cited by 234
Späni, C., Suter, T., Derungs, R., Ferretti, M. T., Welt, T., Wirth, F., Gericke, C., Nitsch, R. M., & Kulic, L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0251-x · Cited by 88
Cited by
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
“In fact, it is important to note that several PD-1 antibody inhibitors developed for other indications activate the peripheral immune system, but fail to modulate monocyte-derived macrophage infiltration and progression of brain Aβ pathology in three different models of AD [399,400].”
BackgroundCui, W., Sun, C., Ma, Y., Wang, S., Wang, X., & Zhang, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00444 · Cited by 220
Peripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
Kummer, M. P., Ising, C., Kummer, C., Sarlus, H., Griep, A., Vieira‐Saecker, A., Schwartz, S., Halle, A., Brückner, M., Händler, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108662 · Cited by 127
Poudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Metadata
- Authors
- Latta‐Mahieu, M., Elmer, B., Bretteville, A., Wang, Y., Lopez‐Grancha, M., Goniot, P., Moindrot, N., Ferrari, P., Blanc, V., Schussler, N., Brault, E., Roudières, V., Blanchard, V., Yang, Z., Barneoud, P., Bertrand, P., Roucourt, B., Carmans, S., Bottelbergs, A., Mertens, L., Wintmolders, C., Larsen, P., Hersley, C., McGathey, T., Racke, M. M., Liu, L., Lu, J., O'Neill, M. J., Riddell, D. R., Ebneth, A., Nabel, G. J., & Pradier, L.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2017-11-14
- Volume
- 66
- Issue
- 3
- Pages
- 492-504
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2770984357
- Cited by
- 64
- References
- 14
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.